Literature DB >> 32559724

Matched pair analysis to evaluate the impact of hospitalization during radiation therapy as an early marker of survival in head and neck cancer patients.

Hye Ri Han1, Gregory M Hermann2, Sung Jun Ma3, Austin J Iovoli4, Kimberly E Wooten5, Hassan Arshad6, Vishal Gupta7, Ryan P McSpadden8, Moni A Kuriakose9, Michael R Markiewicz10, Jon M Chan11, Mary E Platek12, Andrew D Ray13, Fangyi Gu14, Wesley L Hicks15, Elizabeth A Repasky16, Anurag K Singh17.   

Abstract

BACKGROUND: Complications from radiotherapy (RT) alone or combined with surgery and/or chemotherapy for head and neck cancer (HNC) sometimes necessitate hospitalization. Our aim was to evaluate the frequency, cause, and survival outcomes associated with hospitalizations in patients undergoing RT for HNC. PATIENTS AND METHODS: Using a retrospective single-institution database, we reviewed hospitalization records of HNC patients treated at Roswell Park Comprehensive Cancer Center with definitive or post-operative RT between 2003 and 2017. Patients who were admitted during treatment and within 90-days post-RT were identified. Multivariate analyses, Kaplan-Meier statistics, and analysis on propensity score matching were performed to obtain matched-pair, after matching baseline characteristics, such as age, gender, smoking, tumor staging, p16 status, and treatments received.
RESULTS: 839 patients were eligible for analysis. Median follow-up was 34.8 months (Interquartile range [IQR] 15.6-64.8). 595 (71%) received definitive RT and 244 (29%) received adjuvant RT. Chemotherapy was used in 671 patients (80%). 171 patients (20%) had at least one hospitalization. Dehydration (40%) and fever (29%) were the most frequent causes of admission. Hospitalized patients had significantly worse overall survival (OS) (Hazards ratio [HR] 1.61, 95% CI 1.26-2.07, p < 0.001) and cancer-specific survival (CSS) (HR 1.45, 95% CI 1.07-1.95, p = 0.02). 163 matched pairs had median follow-up of 58.6 months (IQR 37.6-85.0). Median OS was 34.5 months (IQR 13.3-58.0) for hospitalized versus 44.2 months (IQR 20.3-78.7) for non-hospitalized patients (p = 0.01).
CONCLUSION: This study reveals significantly worse OS and CSS for patients hospitalized during RT for HNC. Hospitalization may be an early marker for worse survival.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer specific survival; Carcinoma; Head and neck cancer; Hospitalization; Overall survival; Radiotherapy; Response to treatment; SCC; SCCHN; Squamous cell

Year:  2020        PMID: 32559724      PMCID: PMC7738364          DOI: 10.1016/j.oraloncology.2020.104854

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  34 in total

1.  Evaluating the role of prophylactic gastrostomy tube placement prior to definitive chemoradiotherapy for head and neck cancer.

Authors:  Allen M Chen; Bao-Qing Li; Derick H Lau; D Gregory Farwell; Quang Luu; Kerri Stuart; Kathleen Newman; James A Purdy; Srinivasan Vijayakumar
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-16       Impact factor: 7.038

2.  Patient-reported financial toxicity and adverse medical consequences in head and neck cancer.

Authors:  Whitney H Beeler; Emily L Bellile; Keith A Casper; Elizabeth Jaworski; Nicholas J Burger; Kelly M Malloy; Matthew E Spector; Andrew G Shuman; Andrew Rosko; Chaz L Stucken; Steven B Chinn; Aleksandar F Dragovic; Christina H Chapman; Dawn Owen; Shruti Jolly; Carol R Bradford; Mark E P Prince; Francis P Worden; Reshma Jagsi; Michelle L Mierzwa; Paul L Swiecicki
Journal:  Oral Oncol       Date:  2019-12-23       Impact factor: 5.337

3.  Incidence of hospitalization in patients with head and neck cancer treated with intensity-modulated radiation therapy.

Authors:  Diane C Ling; Peyman Kabolizadeh; Dwight E Heron; James P Ohr; Hong Wang; Jonas Johnson; Gregory J Kubicek
Journal:  Head Neck       Date:  2015-06-22       Impact factor: 3.147

4.  Predictive factors of survival and treatment tolerance in older patients treated with chemotherapy and radiotherapy for locally advanced head and neck cancer.

Authors:  Houda Bahig; Bernard Fortin; Moein Alizadeh; Louise Lambert; Edith Filion; Louis Guertin; Tareck Ayad; Apostolos Christopoulos; Eric Bissada; Denis Soulières; Francine Gaba Idiamey; Phuc Felix Nguyen-Tan
Journal:  Oral Oncol       Date:  2015-03-18       Impact factor: 5.337

5.  Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial.

Authors:  Jens Overgaard; Bidhu Kaylan Mohanti; Naseem Begum; Rubina Ali; Jai Prakash Agarwal; Maire Kuddu; Suman Bhasker; Hideo Tatsuzaki; Cai Grau
Journal:  Lancet Oncol       Date:  2010-04-08       Impact factor: 41.316

6.  Haemoglobin and creatinine values as prognostic factors for outcome of concurrent radiochemotherapy in locally advanced head and neck cancers : Secondary results of two European randomized phase III trials (ARO 95-06, SAKK 10/94).

Authors:  Pirus Ghadjar; Christoph Pöttgen; Daniela Joos; Stefanie Hayoz; Michael Baumann; Stephan Bodis; Wilfried Budach; Gabriela Studer; Carmen Stromberger; Frank Zimmermann; David Kaul; Ludwig Plasswilm; Heidi Olze; Jacques Bernier; Peter Wust; Daniel M Aebersold; Volker Budach
Journal:  Strahlenther Onkol       Date:  2016-06-20       Impact factor: 3.621

7.  Impact of nutrition support on treatment outcome in patients with locally advanced head and neck squamous cell cancer treated with definitive radiotherapy: a secondary analysis of RTOG trial 90-03.

Authors:  Rachel Rabinovitch; Barbara Grant; Brian A Berkey; David Raben; Kie Kian Ang; Karen K Fu; Jay S Cooper
Journal:  Head Neck       Date:  2006-04       Impact factor: 3.147

8.  Managing chemotherapy-induced nausea and vomiting in head and neck cancer patients receiving cisplatin chemotherapy with concurrent radiation.

Authors:  Jordan Stinson; Kelvin Chan; Justin Lee; Ronald Chow; Paul Cheon; Angie Giotis; Mark Pasetka; Bo Angela Wan; Edward Chow; Carlo DeAngelis
Journal:  Ann Palliat Med       Date:  2017-03-21

9.  Adrenergic Receptor Signaling Regulates the Response of Tumors to Ionizing Radiation.

Authors:  Cameron R MacDonald; Mark J Bucsek; Guanxi Qiao; Minhui Chen; Lauren Evans; Daniel J Greenberg; Taylor P Uccello; Nicholas G Battaglia; Bonnie L Hylander; Anurag K Singh; Edith M Lord; Scott A Gerber; Elizabeth A Repasky
Journal:  Radiat Res       Date:  2019-04-25       Impact factor: 2.841

10.  Adrenergic stress constrains the development of anti-tumor immunity and abscopal responses following local radiation.

Authors:  Minhui Chen; Guanxi Qiao; Bonnie L Hylander; Hemn Mohammadpour; Xiang-Yang Wang; John R Subjeck; Anurag K Singh; Elizabeth A Repasky
Journal:  Nat Commun       Date:  2020-04-14       Impact factor: 14.919

View more
  2 in total

1.  Intravenous fluids for pain management in head and neck cancer patients undergoing chemoradiation.

Authors:  Charlotte I Rivers; Austin J Iovoli; Udit Chatterjee; Gregory M Hermann; Anurag K Singh
Journal:  Ann Transl Med       Date:  2021-05

2.  Matched pair analysis to evaluate weight loss during radiation therapy for head and neck cancer as a prognostic factor for survival.

Authors:  Hye Ri Han; Gregory M Hermann; Sung Jun Ma; Austin J Iovoli; Kimberly E Wooten; Hassan Arshad; Vishal Gupta; Ryan P McSpadden; Moni A Kuriakose; Michael R Markiewicz; Jon M Chan; Mary E Platek; Andrew D Ray; Fangyi Gu; Wesley L Hicks; Anurag K Singh
Journal:  Ann Transl Med       Date:  2021-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.